Pfizer raised its forecast for COVID-19 vaccine sales in 2026. On November 3, the company reported strong third-quarter results, citing strong performance and commercial momentum. It also raised its full-year guidance for revenue and adjusted diluted EPS. The CEO noted continued progress in the obesity program and recent milestones in oncology.
The company hiked its 2026 adjusted EPS outlook as sales growth in Eliquis and Vyndaqel offset declining revenue from COVID products and Prevnar.
Read the full storyThe increase in the overall forecast came alongside a cut in expected revenue from COVID-19 products to about $4 billion, while the company left its earnings-per-share guidance unchanged.